” Moderna’s mRNA flu vaccine approved by FDA. When is it available? “
The Food and Drug Administration (FDA) has approved Moderna’s mFLUSIVA, the first mRNA-based flu vaccine, for adults ages 50 and older.
mRNA flu vaccines can be produced more quickly than traditional egg-based vaccines, which may help with matching to rapidly changing influenza virus strains.
Experts advise that mFLUSIVA provides another option protecting against flu, but it should not replace every flu vaccine.
The FDA has recently approved Moderna’s mRNA flu vaccine. The vaccine, known as mFLUSIVA (mRNA-1010), is designed to protect adults ages 50 years and olderTrusted Source against seasonal flu. It is the first mRNA-based flu vaccine, using similar technology as the mRNA COVID-19 vaccine.
The FDA approved the vaccine based on the results of a phase 3 clinical trial involving more than 40,000 adults ages 50 and older across 11 countries. Around half of the participants received mFLUSIVA, and the other half received a standard-dose licensed flu vaccine.
The researchers concluded that mFLUSIVA was superior to the standard-dose licensed flu vaccine in preventing flu-like illness confirmed by real-time polymerase chain reaction (RT-PCR) lab tests.
The vaccine was also granted accelerated approval for use in adults ages 65 years and older. This was following a clinical trial involving over 2,900 adults in the United States. The study evaluated how well the immune system responded to mFLUSIVA compared with a high dose inactivated flu shot.
More Information at:
https://www.medicalnewstoday.com/articles/modernas-mrna-flu-vaccine-approved-fda-when-available
